Ignite Creation Date:
2025-12-24 @ 6:29 PM
Ignite Modification Date:
2025-12-30 @ 3:10 AM
Study NCT ID:
NCT00920868
Status:
COMPLETED
Last Update Posted:
2016-02-03
First Post:
2009-06-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib
Sponsor:
Herbert Hurwitz, MD
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
Pro00010354
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |